Musashi–1—A Stemness RBP for Cancer Therapy?

Bley, Nadine; Hmedat, Ali; Müller, Simon; Rolnik, Robin; Rausch, Alexander; Lederer, Marcell; Hüttelmaier, Stefan

doi:10.3390/biology10050407

Cited by 15 publications

(11 citation statements)

References 135 publications

(230 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSI1 has been recognized to be a stem cell marker that mediates a balance between cell selfrenewal and differentiation. Simultaneously, it is also involved in tumorigenesis and has been identified to be highly expressed in various tumor types such as gastric cancer, esophageal cancer, cervical cancer, colorectal cancer, and glioblastoma [48][49][50]. Furthermore, it has been reported that MSI1 can be used as a therapeutic target and diagnostic marker for lung cancer [51].…”

Section: Discussionmentioning

confidence: 99%

Functions of long non-coding RNA LNC11649 in non-small cell lung cancer cells as a reprocessed form of MALAT1

Qi¹,

Zhao²,

Qi³

2022

neo

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) have received much attention concerning their expression mechanisms in tumor formation. It is known that lncRNAs are involved in the occurrence, development, and prognosis of various tumors, including lung cancer. In our study, one non-coding RNA, LNC11649 (649 nt in length), was identified in non-small cell lung cancer (NSCLC) by PacBio third-generation sequencing technology. Both Northern blot and quantitative PCR analyses confirmed the presence of LNC11649 in NSCLC tissues and cells with high expression. Its sequence was found to be highly homologous to lncRNA MALAT1. Knocking down MALAT1 could lead to a significant downregulation of LNC11649 content, revealing the possibility that LNC11649 could originate from MALAT1 reprocessing. RNA immunoprecipitation and electrophoretic mobility shift assays confirmed an interaction between LNC11649 and the MSI1 protein. Further experiments revealed that LNC11649 promoted the cytoplasmic distribution of MSI1 through its interaction with MSI1 and then activated the Akt signaling pathway to regulate the proliferation and migration of NSCLC cells. Our study reveals the possibility that LNC11649 plays a cancer-promoting role as a reprocessed form of MALAT1 in NSCLC cells and suggests that the MALAT1/LNC11649/MSI1/Akt regulatory axis becomes a potential therapeutic target for lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Functions of long non-coding RNA LNC11649 in non-small cell lung cancer cells as a reprocessed form of MALAT1

Qi¹,

Zhao²,

Qi³

2022

neo

View full text Add to dashboard Cite

show abstract

“…Some of these proteins, including OCT4, MYC, KLF4, and SOX2 (Yamanaka factors), are universal, considering that they are typical of both cancer and normal stem cells and are considered essential for stem-related phenotypes [ 107 ]. The regulation of other markers, though, for instance, NANOG, BMI-1, SNAIL, ALDHs, LGR5, CXCR4, REX-1, Musashi-1, LETM1, and C-met, is considered to be dependent on both the cancer type and the specific phenotype of the CSCs that we want to analyze (e.g., drug-resistant, tumorigenic, metastatic) [ 35 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 ]. Studying the expression of specific genes both at the transcriptional and translation level, as well as the activity and localization of these proteins, is useful in assessing the enrichment of CSC properties [ 118 , 119 , 120 , 121 , 122 , 123 ].…”

Section: Cancer Stem Cells (Cscs)mentioning

confidence: 99%

The Concept of Cancer Stem Cells: Elaborating on ALDH1B1 as an Emerging Marker of Cancer Progression

Tsochantaridis

Roupas

Mohlin

et al. 2023

Life

View full text Add to dashboard Cite

Cancer is a multifactorial, complex disease exhibiting extraordinary phenotypic plasticity and diversity. One of the greatest challenges in cancer treatment is intratumoral heterogeneity, which obstructs the efficient eradication of the tumor. Tumor heterogeneity is often associated with the presence of cancer stem cells (CSCs), a cancer cell sub-population possessing a panel of stem-like properties, such as a self-renewal ability and multipotency potential. CSCs are associated with enhanced chemoresistance due to the enhanced efflux of chemotherapeutic agents and the existence of powerful antioxidant and DNA damage repair mechanisms. The distinctive characteristics of CSCs make them ideal targets for clinical therapeutic approaches, and the identification of efficient and specific CSCs biomarkers is of utmost importance. Aldehyde dehydrogenases (ALDHs) comprise a wide superfamily of metabolic enzymes that, over the last years, have gained increasing attention due to their association with stem-related features in a wide panel of hematopoietic malignancies and solid cancers. Aldehyde dehydrogenase 1B1 (ALDH1B1) is an isoform that has been characterized as a marker of colon cancer progression, while various studies suggest its importance in additional malignancies. Here, we review the basic concepts related to CSCs and discuss the potential role of ALDH1B1 in cancer development and its contribution to the CSC phenotype.

show abstract

“…Downstream proteins of Notch interact with a myriad of different factors involved in other pathways to maintain CSCs and progenitors. One of these factors is Musashi-1, an RNA-binding protein known for its role in CSC maintenance [ 59 ]. Elevated levels of Musashi-1 have been observed in eCSCs and inhibition of this protein results in downregulation of Notch-1 signaling which triggers apoptosis in endometrial cancer cells (ECCs) [ 60 ].…”

Section: Pathways Involved In Ecsc Maintenancementioning

confidence: 99%

Bone Marrow-Derived Cells in Endometrial Cancer Pathogenesis: Insights from Breast Cancer

Ferrer

Einstein

Morelli

2022

Cells

View full text Add to dashboard Cite

Endometrial cancer is the most common gynecological cancer, representing 3.5% of all new cancer cases in the United States. Abnormal stem cell-like cells, referred to as cancer stem cells (CSCs), reside in the endometrium and possess the capacity to self-renew and differentiate into cancer progenitors, leading to tumor progression. Herein we review the role of the endometrial microenvironment and sex hormone signaling in sustaining EC progenitors and potentially promoting dormancy, a cellular state characterized by cell cycle quiescence and resistance to conventional treatments. We offer perspective on mechanisms by which bone marrow-derived cells (BMDCs) within the endometrial microenvironment could promote endometrial CSC (eCSC) survival and/or dormancy. Our perspective relies on the well-established example of another sex hormone-driven cancer, breast cancer, in which the BM microenvironment plays a crucial role in acquisition of CSC phenotype and dormancy. Our previous studies demonstrate that BMDCs migrate to the endometrium and express sex hormone (estrogen and progesterone) receptors. Whether the BM is a source of eCSCs is unknown; alternatively, crosstalk between BMDCs and CSCs within the endometrial microenvironment could be an additional mechanism supporting eCSCs and tumorigenesis. Elucidating these mechanisms will provide avenues to develop novel therapeutic interventions for EC.

show abstract

Musashi–1—A Stemness RBP for Cancer Therapy?

Cited by 15 publications

References 135 publications

Functions of long non-coding RNA LNC11649 in non-small cell lung cancer cells as a reprocessed form of MALAT1

Functions of long non-coding RNA LNC11649 in non-small cell lung cancer cells as a reprocessed form of MALAT1

The Concept of Cancer Stem Cells: Elaborating on ALDH1B1 as an Emerging Marker of Cancer Progression

Bone Marrow-Derived Cells in Endometrial Cancer Pathogenesis: Insights from Breast Cancer

Contact Info

Product

Resources

About